Research programme: immunomodulator therapeutics - Realm Therapeutics

Drug Profile

Research programme: immunomodulator therapeutics - Realm Therapeutics

Alternative Names: PR 013; PR 031

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Puricore
  • Developer Realm Therapeutics
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders
  • Research Inflammation

Most Recent Events

  • 02 Aug 2017 Realm files an IND application with the US FDA for Allergic conjunctivitis
  • 02 Aug 2017 Realm plans a phase II trial for Allergic conjunctivitis (In children, In adolescents, In adults, In the elderly) in USA
  • 28 Feb 2017 Realm Therapeutics announces intention to submit IND to US FDA in Q3 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top